Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how chronic stress affects the effectiveness of a type of cancer treatment called immune checkpoint inhibitors (ICIs) in patients with advanced gastric cancer. Gastric cancer is a serious illness, and understanding the role of psychological factors like stress could help improve treatment outcomes. The trial aims to see if patients with high levels of stress respond differently to treatment compared to those with lower stress levels. Researchers will also look at how stress impacts the quality of life after surgery and overall survival.

To participate in this trial, individuals need to be between 18 and 75 years old and have been diagnosed with gastric adenocarcinoma, which is a type of stomach cancer. They should be planning to receive neoadjuvant immunotherapy followed by surgery. Key factors for eligibility include being able to provide consent, not having serious mental health issues, and not having undergone recent surgeries or treatments that could interfere with the study. Participants will complete questionnaires about their stress levels and undergo tests to measure their response to treatment and quality of life over time. This study is important because it could lead to better personalized treatments for patients dealing with gastric cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Voluntary signing of informed consent;
• • 18≦ age ≦75 years;
• • Sex: no limitation;
• • Patients with gastric adenocarcinoma diagnosed according to the 15th edition of the Japanese gastric cancer statute, 2017, after endoscopic biopsy of the primary lesion;
• • Patients requiring preoperative immune checkpoint inhibitor therapy at the discretion of the treating physician, followed by radical gastrectomy.
• Exclusion Criteria:
• • Women who are pregnant or breastfeeding;
• • Serious mental illness;
• • History of upper abdominal surgery (except for laparoscopic cholecystectomy) ;
• • Patients with gastric cancer who do not wish to undergo neoadjuvant immunotherapy;
• • Patients with a history of continuous systemic corticosteroid therapy within the past 1 month;
• • Patients with active infection, active or refractory autoimmune disease, or uncontrolled systemic disease;
• • Patients at the discretion of the investigator, were deemed unsuitable for participation in this study.